Opsens Inc. (“Opsens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) announced it has developed a product that will allow the diagnosis of coronary heart blockages with the heart at rest. Filing for regulatory approvals has been completed in targeted territories. Opsens plans to begin commercialization by the end of calendar year 2018.

In recent years, the measurement of Fractional Flow Reserve (“FFR”) as a method of assessing intracoronary pressure, has gained credibility and popularity following the publication of clinical studies demonstrating its benefits for patients’ health. FFR is used to assess the incidence of coronary artery stenosis before selecting a treatment. This measurement is done in the context where the heart is stimulated with the injection of medication. In addition to this interest in FFR, cardiologists have also shown interest in measuring intracoronary pressure to make a diagnosis with the heart at rest, without injection of medication.

Medical publications have highlighted the equivalence of several algorithms using the measurement of pressure at rest. These publications are expected to accelerate the adoption of resting pressure measurement methods in the interventional cardiology community.

This new product, named dPR, will be Opsens’ resting pressure measurement method.  It will be available through the OptoMonitor and will work in combination with the OptoWire.

With strong intellectual property, Opsens has the potential for significant market share capture through product innovation and differentiation from current electric wires. The FFR market currently stands at approximately US$500M.